Belite Bio: Up to 203,699 ADSs from warrant exercises
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Belite Bio, Inc. (BLTE) is registering the issuance of up to 203,699 ADSs, each representing one ordinary share, when holders exercise outstanding warrants. Each warrant has an exercise price of US$18.00 per ADS, is exercisable at any time on or after issuance, and expires on the fifth anniversary of its issuance. The registration continues coverage for the remaining unexercised warrants from the 2023 offering.
Belite estimates it would receive approximately US$3.67 million if all covered warrants were exercised for cash; cashless exercises produce no proceeds. Net proceeds are intended for working capital and other general corporate purposes. Exercise is limited if it would cause a holder and its affiliates to exceed 4.99% beneficial ownership immediately after exercise. Holders may adjust the limit on at least 61 days’ prior written notice, up to 9.99%. The warrants have no established trading market, and holders have no ADS shareholder rights until exercise.
Filing Explained
The filing addresses registration coverage for potential exercise; it does not itself exercise warrants or issue ADSs.
The earlier registration expired on
If a registration statement or its prospectus is not effective or available when a holder exercises, the holder may choose a cashless exercise and receive a formula-based net number of ADSs instead of paying cash.
Key Figures
Key Terms
cashless exercise financial
passive foreign investment company financial
qualified electing fund election financial
automatic shelf registration statement regulatory
fundamental transaction technical
Offering Details
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many BLTE ADSs are covered by the warrant registration?
How much could Belite Bio receive from BLTE warrant exercises?
What is the BLTE warrant exercise price and expiration?
What ownership limit applies when exercising Belite Bio warrants?
AI-generated analysis. How Rhea-AI works. Not financial advice.
(to Prospectus dated January 27, 2025)
Exercise of Outstanding Warrants
| |
ABOUT THIS PROSPECTUS
|
| | | | S-2 | | |
| |
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
|
| | | | S-3 | | |
| |
PROSPECTUS SUPPLEMENT SUMMARY
|
| | | | S-5 | | |
| |
RISK FACTORS
|
| | | | S-7 | | |
| |
USE OF PROCEEDS
|
| | | | S-9 | | |
| |
DESCRIPTION OF THE WARRANTS
|
| | | | S-10 | | |
| |
PLAN OF DISTRIBUTION
|
| | | | S-12 | | |
| |
MATERIAL TAX CONSIDERATIONS
|
| | | | S-13 | | |
| |
LEGAL MATTERS
|
| | | | S-20 | | |
| |
EXPERTS
|
| | | | S-21 | | |
| |
WHERE YOU CAN FIND MORE INFORMATION
|
| | | | S-22 | | |
| |
INCORPORATION OF INFORMATION BY REFERENCE
|
| | | | S-23 | | |
| | | |
Page
|
| |||
|
ABOUT THIS PROSPECTUS
|
| | | | 1 | | |
|
OUR COMPANY
|
| | | | 3 | | |
|
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
|
| | | | 9 | | |
|
THE OFFERING
|
| | | | 11 | | |
|
RISK FACTORS
|
| | | | 13 | | |
|
USE OF PROCEEDS
|
| | | | 17 | | |
|
CAPITALIZATION
|
| | | | 18 | | |
|
DESCRIPTION OF SHARE CAPITAL
|
| | | | 19 | | |
|
DESCRIPTION OF AMERICAN DEPOSITARY SHARES
|
| | | | 30 | | |
|
TAXATION
|
| | | | 40 | | |
|
SELLING SHAREHOLDERS
|
| | | | 41 | | |
|
PLAN OF DISTRIBUTION
|
| | | | 44 | | |
|
WHERE YOU CAN FIND MORE INFORMATION
|
| | | | 46 | | |
|
INCORPORATION BY REFERENCE
|
| | | | 47 | | |
|
ENFORCEABILITY OF CIVIL LIABILITIES
|
| | | | 48 | | |
|
LEGAL MATTERS
|
| | | | 51 | | |
|
EXPERTS
|
| | | | 52 | | |
475, San Diego, CA 92130
Tel: +1-858-246-6240
Attention: Chief Financial Officer
Up to 1,953,124 American Depositary Shares representing 1,953,124 Ordinary Shares
issuable upon exercise of the Warrants
| | | |
Page
|
| |||
|
ABOUT THIS PROSPECTUS
|
| | | | 1 | | |
|
OUR COMPANY
|
| | | | 3 | | |
|
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
|
| | | | 9 | | |
|
THE OFFERING
|
| | | | 11 | | |
|
RISK FACTORS
|
| | | | 13 | | |
|
USE OF PROCEEDS
|
| | | | 17 | | |
|
CAPITALIZATION
|
| | | | 18 | | |
|
DESCRIPTION OF SHARE CAPITAL
|
| | | | 19 | | |
|
DESCRIPTION OF AMERICAN DEPOSITARY SHARES
|
| | | | 30 | | |
|
TAXATION
|
| | | | 40 | | |
|
SELLING SHAREHOLDERS
|
| | | | 41 | | |
|
PLAN OF DISTRIBUTION
|
| | | | 44 | | |
|
WHERE YOU CAN FIND MORE INFORMATION
|
| | | | 46 | | |
|
INCORPORATION BY REFERENCE
|
| | | | 47 | | |
|
ENFORCEABILITY OF CIVIL LIABILITIES
|
| | | | 48 | | |
|
LEGAL MATTERS
|
| | | | 51 | | |
|
EXPERTS
|
| | | | 52 | | |
| | | |
As of June 30, 2025
|
| |||||||||
| | | |
Actual
|
| |
As Adjusted
|
| ||||||
| | | |
$’000
|
| |
$’000
|
| ||||||
| Shareholders’ equity | | | | | | | | | | | | | |
|
Share capital
|
| | | | 3 | | | | | | 3 | | |
|
Additional paid-in capital
|
| | | | 288,640 | | | | | | 421,025 | | |
|
Accumulated other comprehensive loss
|
| | | | (514) | | | | | | (514) | | |
|
Accumulated losses
|
| | | | (138,244) | | | | | | (138,244) | | |
|
Total shareholders’ equity
|
| | | | 149,885 | | | | | | 282,270 | | |
|
Total capitalization
|
| | | | 149,885 | | | | | | 282,270 | | |
|
Service
|
| |
Fees
|
|
|
•
To any person to which ADSs are issued or to any person to which a distribution is made in respect of ADS distributions pursuant to stock dividends or other free distributions of stock, bonus distributions, stock splits or other distributions (except where converted to cash)
|
| | Up to US$0.05 per ADS issued | |
|
•
Cancellation of ADSs, including the case of termination of the deposit agreement
|
| | Up to US$0.05 per ADS cancelled | |
|
•
Distribution of cash dividends
|
| | Up to US$0.05 per ADS held | |
|
•
Distribution of cash entitlements (other than cash dividends) and/or cash proceeds from the sale of rights, securities and other entitlements
|
| | Up to US$0.05 per ADS held | |
|
•
Distribution of ADSs pursuant to exercise of rights
|
| | Up to US$0.05 per ADS held | |
|
•
Distribution of securities other than ADSs or rights to purchase additional ADSs
|
| | Up to US$0.05 per ADS held | |
|
•
Depositary services
|
| | Up to US$0.05 per ADS held on the applicable record date(s) established by the depositary bank | |
|
If we:
|
| |
Then:
|
|
| Change the nominal or par value of our ordinary shares | | | The cash, shares or other securities received by the depositary will become deposited securities. | |
| Reclassify, split up or consolidate any of the deposited securities | | | Each ADS will automatically represent its equal share of the new deposited securities. | |
| Distribute securities on the ordinary shares that are not distributed to you, or Recapitalize, reorganize, merge, liquidate, sell all or substantially all of our assets, or take any similar action | | | The depositary may distribute some or all of the cash, shares or other securities it received. It may also deliver new ADSs or ask you to surrender your outstanding ADRs in exchange for new ADRs identifying the new deposited securities. | |
|
Name of Selling Shareholders
|
| |
ADSs/Ordinary
Shares Beneficially Owned Prior to Completion of the Resale Offering(1) |
| |
ADSs/Ordinary
Shares Offered Pursuant to this Prospectus(2) |
| |
ADSs/Ordinary
Shares Beneficially Owned Upon Completion of the Resale Offering(3) |
| |
Percentage of
ADSs/Ordinary Shares Beneficially Owned Upon Completion of the Resale Offering(3) |
| ||||||||||||
|
RA Capital Healthcare Fund, L.P.(4)
|
| | | | 1,750,000 | | | | | | 1,750,000 | | | | | | — | | | | | | — | | |
|
Entities associated with RTW Investments, LP(5)
|
| | | | 625,000 | | | | | | 625,000 | | | | | | — | | | | | | — | | |
|
Entities Affiliated with Vestal Point Capital, LP(6)
|
| | | | 625,000 | | | | | | 625,000 | | | | | | — | | | | | | — | | |
|
Mutual Fund Series Trust, on behalf of Eventide Healthcare & Life Sciences Fund(7)
|
| | | | 390,624 | | | | | | 390,624 | | | | | | — | | | | | | — | | |
|
Entities affiliated with Marshall
Wace(8) |
| | | | 375,000 | | | | | | 375,000 | | | | | | — | | | | | | — | | |
|
Soleus Capital Master Fund, L.P.(9)
|
| | | | 238,312 | | | | | | 140,624 | | | | | | 97,688 | | | | | | * | | |
San Diego, CA 92130
Tel: +1-858-246-6240
Attention: Chief Financial Officer
| | | |
Amount
|
| |||
| Expenses | | | | | | | |
|
SEC Registration Fee
|
| | | $ | 48,124.58 | | |
|
Printing and engraving expenses
|
| | | | * | | |
|
Legal Fees and expenses
|
| | | | * | | |
|
Accounting fees and expenses
|
| | | | * | | |
|
Total
|
| | | $ | * | | |